The global CRISPR/Cas9
licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier & Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Contact us

"This is transformative technology that allows the recoding of life and editing"

Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 85 issued patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.
Learn more

Latest news

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement
Posted on
ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 ...
LSPN Boston 2023: Life Science IP Review
Posted on
“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is ...
BIO Europe, Basel 2023: Our thoughts
Posted on
#BIO Europe is one of the most important Life Science events for people in the industry to attend. This year was ...
CRISPR-Made Greener Products and Processes in Industrial Biotechnology
Posted on
Find out what role #CRISPR has to play in the new bio-industrial revolution in our latest article on #synbio and ...
Five things you need to know about using CRISPR/Cas9 commercially
Posted on
Here are the 5 key facts you need to know, so you can secure the licenses that will protect your ...
Welcome to the CRISPR Powerhouse – the power & flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline.
Posted on
In The Medicine Maker, ERS Genomics CEO, Eric Rhodes explores the power and flexibility of CRISPR/Cas9 for the antibody manufacturing ...
Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada
Posted on
Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions ...
Crown Bioscience & ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
Posted on
  San Diego, USA and Dublin, Ireland 8 December 2022, Crown Bioscience, Inc and ERS Genomics Limited (‘ERS’) have signed ...
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
Posted on
Dublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. ...
New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL
Posted on
Dublin, Ireland, 17 November 2022: ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive ...